Anzeige
Mehr »
Donnerstag, 24.07.2025 - Börsentäglich über 12.000 News
Neubewertung voraus? Wird die Aktivierung der EU-Lizenz zum Kurs-Katalysator für die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AM00 | ISIN: SE0008241558 | Ticker-Symbol: 4A1
Frankfurt
23.07.25 | 08:09
0,819 Euro
+2,25 % +0,018
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERENO SCIENTIFIC AB Chart 1 Jahr
5-Tage-Chart
CERENO SCIENTIFIC AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,8390,86923.07.

Aktuelle News zur CERENO SCIENTIFIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.07.Cereno Scientific - Phase II calling for CS014 after Phase I success215Cereno Scientific reported positive Phase I readouts for CS014, its novel HDAC inhibitor, paving the way for Phase II studies in idiopathic pulmonary fibrosis (IPF). The candidate demonstrated favourable...
► Artikel lesen
15.07.Cereno Scientific AB: Cereno Scientific announces positive topline results from Phase I trial of CS014 - a novel HDAC inhibitor - supporting advancement into Phase II59Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive...
► Artikel lesen
30.06.Cereno Scientific shares that the top-line results of the CS014 Phase I trial will be communicated in mid-July4
23.06.Cereno Scientific - Improved liquidity with latest debt financing263Cereno Scientific has bolstered its liquidity position through a SEK25m loan facility secured from new Danish investors Venusat and SAJ Finans. Concurrently, the company executed an addendum to its...
► Artikel lesen
20.06.Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II1
17.06.Cereno Scientific - Four-month EAP data support CS1 plans273Cereno Scientific has announced encouraging four-month follow-up data from its Expanded Access Program (EAP) for CS1, a first-in-class HDAC inhibitor being developed to treat pulmonary arterial hypertension...
► Artikel lesen
16.06.Cereno Scientific AB: Cereno Scientific shares 4-month follow-up data from Expanded Access Program in line with Phase IIa trial results of CS1 in rare disease PAH145Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced 4-month...
► Artikel lesen
10.06.Cereno Scientific AB: Cereno Scientific shares the report from Annual General Meeting 2025164Today, June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairman of the Annual General Meeting (the...
► Artikel lesen
CERENO SCIENTIFIC Aktie jetzt für 0€ handeln
27.05.Cereno Scientific - Firing on all cylinders382In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement...
► Artikel lesen
27.05.Cereno Scientific is nominated and shortlisted for 'Company of the Year' in the European Mediscience Awards 20251
23.05.Cereno Scientific AB: Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH)149Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
22.05.Cereno Scientific AB: Cereno Scientific publishes Interim Report for Q1 2025 (January 1 - March 31, 2025)233Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
15.05.Cereno Scientific publishes Annual Report for 20241
13.05.Cereno Scientific presented CS1's Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 20252
09.05.Cereno Scientific give notice to attend the Annual General Meeting 20251
07.05.Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 20251
07.05.Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 20252
07.05.Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm1
23.04.Cereno Scientific - CS1 takes another step towards Phase IIb327Cereno Scientific has successfully completed its planned Type C meeting with the FDA for lead asset CS1. The minutes from the meeting will be available after 30 days, but Cereno has indicated that the...
► Artikel lesen
22.04.Cereno Scientific aligns with FDA on CS1 development3
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1